Almon Einat Brill

Avg. Two Year Performance

No purchase track record

35% Avg. Sale Return

16% Compound

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	(4%)	< 1%	13%	17%	35%
Sale Success Rate	2 of 7	2 of 7	4 of 7	4 of 7	5 of 7

Protalix BioTherapeutics, I...

Drugs » Biotechnology

SVP, Chief Development Officer:

Holdings: 185.0K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--